Percutaneous Peripheral Nerve Stimulation in Acute Pain Medicine

2017 ◽  
Vol 7 (2) ◽  
pp. 220-226 ◽  
Author(s):  
Brian Ohlendorf ◽  
Stuart A. Grant
Biomedicines ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 18
Author(s):  
Alaa Abd-Elsayed ◽  
Ryan S. D’Souza

Peripheral nerve stimulation (PNS) involves the application of electrical stimulation near the proximity of peripheral nerves. Although the mechanism of action remains unknown, PNS likely modulates both the central and peripheral nervous systems to provide analgesia for a wide variety of pain disorders involving the head, extremities, and trunk. Historically, PNS was not utilized widely due to underwhelming results from earlier studies. However, significant innovations in device technologies, including improved implantation techniques, hardware miniaturization, and externalized pulse generators, have led to the resurgence of PNS in the field of pain medicine. This editorial briefly reviews the evolution of PNS in the field of pain medicine and highlights areas for future investigation.


2020 ◽  
Vol 133 (5) ◽  
pp. 1127-1149 ◽  
Author(s):  
Brian M. Ilfeld ◽  
John J. Finneran

Two regional analgesic modalities currently cleared by the U.S. Food and Drug Administration hold promise to provide postoperative analgesia free of many of the limitations of both opioids and local anesthetic-based techniques. Cryoneurolysis uses exceptionally low temperature to reversibly ablate a peripheral nerve, resulting in temporary analgesia. Where applicable, it offers a unique option given its extended duration of action measured in weeks to months after a single application. Percutaneous peripheral nerve stimulation involves inserting an insulated lead through a needle to lie adjacent to a peripheral nerve. Analgesia is produced by introducing electrical current with an external pulse generator. It is a unique regional analgesic in that it does not induce sensory, motor, or proprioception deficits and is cleared for up to 60 days of use. However, both modalities have limited validation when applied to acute pain, and randomized, controlled trials are required to define both benefits and risks.


2021 ◽  
pp. 2004033
Author(s):  
Estelle A. Cuttaz ◽  
Christopher A. R. Chapman ◽  
Omaer Syed ◽  
Josef A. Goding ◽  
Rylie A. Green

Sign in / Sign up

Export Citation Format

Share Document